Added to YB: 2025-03-06
Pitch date: 2025-02-25
LLY [neutral]
Eli Lilly and Company
+15.03%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$893.25
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
value
RiverPark Long/Short Opportunity Fund Portfolio Holding: Eli Lilly and Company
LLY (holdings update): Q4 detractor due to $1B+ tirzepatide miss (Mounjaro/Zepbound) from supply chain issues. Huge diabetes/obesity market, demand strong. Reacceleration expected. Broad portfolio in diabetes, oncology, immunology, neuroscience. Kisunla (Alzheimer's) adds growth. Projecting high-teens revenue growth, 4x FCF increase in 5 years.
Read full article (1 min)